Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- XBIOW
- Price
- -
- Stock movement up
- +- (%)
- Company name
- Xenetic Biosciences Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- -
- Ent value
- -5.71M
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 27.44%
- 1 year return
- 69.63%
- 3 year return
- 116.44%
- 5 year return
- -
- 10 year return
- -
Last updated: 2024-12-17
DIVIDENDS
XBIOW does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | -2.27 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | - |
| EPS (TTM) | -3.05 |
| FCF per share (TTM) | -2.22 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 2.52M |
| Gross profit (TTM) | 1.79M |
| Operating income (TTM) | -5.01M |
| Net income (TTM) | -4.70M |
| EPS (TTM) | -3.05 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 71.18% |
| Operating margin (TTM) | -198.71% |
| Profit margin (TTM) | -186.33% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 7.30M |
| Net receivables | 716.38K |
| Total current assets | 8.01M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 9.03M |
| Accounts payable | 283.59K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 1.59M |
| Total liabilities | 1.59M |
| Shareholder's equity | 7.45M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -3.43M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -3.43M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -63.07% |
| Return on Assets | -51.99% |
| Return on Invested Capital | -63.07% |
| Cash Return on Invested Capital | -46.03% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| XBIOW | S&P500 | |
| Current price drop from All-time high | -24.27% | -2.16% |
| Highest price drop | -99.98% | -56.47% |
| Date of highest drop | 9 Dec 2022 | 9 Mar 2009 |
| Avg drop from high | -63.63% | -10.99% |
| Avg time to new high | 85 days | 12 days |
| Max time to new high | 550 days | 1805 days |
COMPANY DETAILS
Marketcap
-
Marketcap category
Small-cap
Description
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase enzyme for use in treatment of cancer; and exclusive license agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase in conjunction with CAR T therapies. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Employees
4
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner